Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P et al (2016) ;13(5):261 – 80. https://doi.org/10.1038/nrgastro.2016.51, PMID: 27095655. https://doi.org/10.1038/nrgastro.2016.51
Blechacz B, Komuta M, Roskams T, Gores GJ (2011) Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 8(9):512–522. https://doi.org/10.1038/nrgastro.2011.131
Article PubMed PubMed Central Google Scholar
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95–111. https://doi.org/10.1038/nrclinonc.2017.157
Article CAS PubMed Google Scholar
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C et al (2018) Global, Regional, and National Cancer incidence, mortality, years of Life Lost, Years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2016: a systematic analysis for the global burden of Disease Study. JAMA Oncol 4(11):1553–1568. https://doi.org/10.1001/jamaoncol.2018.2706
Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145(6):1215–1229. https://doi.org/10.1053/j.gastro.2013.10.013
Article CAS PubMed Google Scholar
Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM (2016) Molecular Pathogenesis and targeted therapies for Intrahepatic Cholangiocarcinoma. Clin Cancer Res 22(2):291–300. https://doi.org/10.1158/1078-0432.CCR-14-3296
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47(9):1003–1010. https://doi.org/10.1038/ng.3375
Article CAS PubMed Google Scholar
Weber SM, Ribero D, O’Reilly EM, Kokudo N, Miyazaki M, Pawlik TM (2015) Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17(8):669–680. https://doi.org/10.1111/hpb.12441
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517 discussion 517-9. https://doi.org/10.1097/00000658-200110000-00010
Article CAS PubMed PubMed Central Google Scholar
Hidalgo E, Asthana S, Nishio H, Wyatt J, Toogood GJ, Prasad KR et al (2008) Surgery for hilar cholangiocarcinoma: the Leeds experience. Eur J Surg Oncol 34(7):787–794. https://doi.org/10.1016/j.ejso.2007.10.005
Article CAS PubMed Google Scholar
Yoo T, Park SJ, Han SS, Kim SH, Lee SD, Kim TH et al (2018) Proximal resection margins: more prognostic than distal resection margins in patients undergoing Hilar Cholangiocarcinoma Resection. Cancer Res Treat 50(4):1106–1113. https://doi.org/10.4143/crt.2017.320
Huggett MT, Passant H, Hurt C, Pereira SP, Bridgewater J, Mukherjee S (2014) Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom. Tumori 100(2):219–224. https://doi.org/10.1177/030089161410000217
Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE 9(12):e115383. https://doi.org/10.1371/journal.pone.0115383
Article CAS PubMed PubMed Central Google Scholar
Tian W, Hu W, Shi X, Liu P, Ma X, Zhao W et al (2020) Comprehensive genomic profile of cholangiocarcinomas in China. Oncol Lett 19(4):3101–3110. https://doi.org/10.3892/ol.2020.11429
Article CAS PubMed PubMed Central Google Scholar
Waseem D, Tushar P (2017) Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes. Ann Hepatol 16(1):133–139. https://doi.org/10.5604/16652681.1226927
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR et al (2017) Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23(6):703–713. https://doi.org/10.1038/nm.4333
Article CAS PubMed PubMed Central Google Scholar
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. https://doi.org/10.1126/scisignal.2004088
Article CAS PubMed PubMed Central Google Scholar
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47(9):1003–1010. https://doi.org/10.1038/ng.3375
Article CAS PubMed Google Scholar
Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of Cholangiocarcinoma. Cancer Discov 7(10):1116–1135. https://doi.org/10.1158/2159-8290.CD-17-0368
Article CAS PubMed PubMed Central Google Scholar
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E et al (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of Cancer. Cell 173(2):291–304e6. https://doi.org/10.1016/j.cell.2018.03.022
Article CAS PubMed PubMed Central Google Scholar
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J et al OncoKB: a Precision Oncology Knowledge Base. JCO Precis Oncol 2017;2017:PO.17.00011. https://doi.org/10.1200/PO.17.00011
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557–588. https://doi.org/10.1038/s41575-020-0310-z
Article PubMed PubMed Central Google Scholar
Xue L, Guo C, Zhang K, Jiang H, Pang F, Dou Y et al (2019) Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in chinese population and potential targets for clinical practice. Hepatobiliary Surg Nutr 8(6):615–622. https://doi.org/10.21037/hbsn.2019.08.05
Article PubMed PubMed Central Google Scholar
Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M et al (2018) Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: potential targets for intervention. Clin Cancer Res 24(17):4154–4161. https://doi.org/10.1158/1078-0432.CCR-18-0078
Article CAS PubMed PubMed Central Google Scholar
Guest RV, Boulter L, Dwyer BJ, Kendall TJ, Man TY, Minnis-Lyons SE et al (2016) Notch3 drives development and progression of cholangiocarcinoma. Proc Natl Acad Sci U S A 113(43):12250–12255. https://doi.org/10.1073/pnas.1600067113
Article CAS PubMed PubMed Central Google Scholar
O’Rourke CJ, Matter MS, Nepal C, Caetano-Oliveira R, Ton PT, Factor VM et al (2020) Identification of a pan-gamma-secretase inhibitor response signature for Notch-Driven Cholangiocarcinoma. Hepatology 71(1):196–213. https://doi.org/10.1002/hep.30816
Article CAS PubMed Google Scholar
Zhang Y, Ma Z, Li C, Wang C, Jiang W, Chang J et al (2022) The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers. Nat Commun 13(1):3061. https://doi.org/10.1038/s41467-022-30708-7
Article CAS PubMed PubMed Central Google Scholar
Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K et al (2015) Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun 6:6120. https://doi.org/10.1038/ncomms7120
Article CAS PubMed Google Scholar
Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM et al (2017) Common molecular subtypes among asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell 32(1):57–70e3. https://doi.org/10.1016/j.ccell.2017.05.009
Article CAS PubMed PubMed Central Google Scholar
Feng F, Wu X, Shi X, Gao Q, Wu Y, Yu Y et al (2021) Comprehensive analysis of genomic alterations of chinese hilar cholangiocarcinoma patients. Int J Clin Oncol 26(4):717–727. https://doi.org/10.1007/s10147-020-01846-z
Article CAS PubMed Google Scholar
Khamko R, Wasenang W, Daduang J, Settasatian C, Limpaiboon T (2022) Combined OPCML and AXL expression as a prognostic marker and OPCML enhances AXL inhibitor in Cholangiocarcinoma. In Vivo 36(3):1168–1177. https://doi.org/10.21873/invivo.12816
Article CAS PubMed PubMed Central Google Scholar
Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN et al (2022) AXL inhibition improves BRAF-targeted treatment in melanoma. Sci Rep 12(1):5076. https://doi.org/10.1038/s41598-022-09078-z
Article CAS PubMed PubMed Central Google Scholar
Zhang S, Xu XS, Yang JX, Guo JH, Chao TF, Tong Y (2018) The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review. Onco Targets Ther 11:509–519. https://doi.org/10.2147/OTT.S150952
Comments (0)